Insulin resistance, diabetic kidney disease, and all-cause mortality in individuals with type 2 diabetes: a prospective cohort study

1Risk of death from any cause and cardiovascular disease (CVD) is significantly higher in patients with type 2 diabetes (T2D) than in people without diabetes, though it varies widely from lower risk, approaching that of the general population, to substantial excess of risk, especially in T2D individuals with younger age, worse glycaemic control, and impaired renal function. In particular, diabetic kidney disease (DKD) is a major contributor to excess mortality in T2D, conferring a very high risk in younger patients and fully accounting for the excess of risk in the older ones.

2However, in the last decades, a decline in all-cause mortality and in the incidence of CVD has been consistently reported in T2D individuals. Patients with T2D from the Swedish National Diabetes Register showed a ~ 20% greater reduction in overall CVD than controls, although fatal outcomes declined to a lesser extent. Likewise, the analysis of data from the National Health Interview Survey Linked Mortality files showed that, among US adults with diabetes, death from any cause declined by 20%, whereas death from CVD decreased by 32% every 10 years. Death rates declined also among nondiabetic individuals, but reductions were significantly greater among people with diabetes, so that differences in all-cause and CVD mortality between individuals with and without diabetes were reduced by about a half.

3Intensified, multifactorial, target-driven treatment has substantially contributed to the decline in mortality in people with T2D, by increasing the years of life gained and the time free from incident CVD as well as by slowing progression of DKD toward end-stage renal disease. Nevertheless, T2D persons still have a large excess in total and CVD mortality suggesting that other risk factors are involved.

4Insulin resistance (IR) is associated with an increased risk of CVD in people with T2D and also in those with type 1 diabetes (T1D). Other than clustering with hyperglycaemia, dyslipidaemia, hypertension, and obesity, which are targeted by multifactorial interventions, IR is associated with endothelial dysfunction and a pro-oxidant, pro-inflammatory, and pro-coagulant environment. In addition, IR is strongly related to DKD and may mediate the increased CVD risk associated with it; the severe insulin-resistant T2D subtype was in fact shown to have the highest risk of developing DKD and coronary artery disease (CAD).

5The independent association between IR and risk of death from any cause has been poorly explored in patients with T2D, at variance with those with T1D. Moreover, contrasting findings have been reported in nondiabetic individuals, with studies showing either a significant association or no association of IR with all-cause mortality.

6This study was designed to evaluate the association between IR and death from any cause, beyond traditional CVD risk factors, established CVD, and particularly DKD, in the large cohort of T2D individuals from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Insulin sensitivity was assessed as estimated glucose disposal rate (eGDR), which was originally validated against the euglycaemic-hyperinsulinemic clamp technique and used in epidemiological studies in individuals with T1D. Specifically, we aimed to assess whether eGDR is independently associated with all-cause mortality in T2D individuals or its relationship with death is mediated through the association with DKD.

7The RIACE is an observational, prospective, cohort study on the impact of estimated glomerular filtration rate (eGFR) on morbidity and mortality in patients with T2D.

8The RIACE population consists of 15,773 Caucasian individuals with type 2 diabetes (after excluding 160 patients with missing or implausible values), consecutively visiting 19 hospital-based, tertiary referral Diabetes Clinics of the National Health Service throughout Italy in the years 2006–2008. Exclusion criteria were dialysis or renal transplantation.

9The vital status of the participants on 31 October 2015 was verified by interrogating the Italian Health Card database (http://sistemats1.sanita.finanze.it/wps/portal/), which provides updated information on all current Italian residents.

10Baseline data were collected using a standardised protocol across participating centres.

11Participants underwent a structured interview in order to collect the following information: age, smoking status, known diabetes duration, co-morbidities, and current glucose-, lipid-, and blood pressure (BP)-lowering treatments.

12Body mass index (BMI) was calculated from weight and height, whereas waist circumference was estimated from log-transformed BMI values using sex-specific linear regression equations derived from waist measurements obtained from 4618 participants, as previously described. BP was measured with a sphygmomanometer with the patients seated with the arm at the heart level and hypertension was defined as systolic BP > 140 mmHg and/or diastolic BP > 90 and/or anti-hypertensive treatment.

13Haemoglobin A1c (HbA1c) was measured by high-performance liquid chromatography using DCCT-aligned methods; triglycerides and total and HDL cholesterol were determined in fasting blood samples by colorimetric enzymatic methods; non-HDL cholesterol was calculated by the following formula: total cholesterol − HDL cholesterol; and LDL cholesterol was calculated by the Friedewald formula. Dyslipidaemia was defined as LDL cholesterol > 2.59 mmol/l and/or treatment with lipid-lowering agents.

14Presence of DKD was assessed by measuring albuminuria and serum creatinine. As previously detailed, albumin excretion rate was obtained from 24-h urine collections or calculated from albumin-to-creatinine ratio in early-morning, first-voided urine samples, using a conversion formula preliminary validated in a subgroup of the RIACE cohort. Albuminuria was measured in fresh urine samples by immunonephelometry or immunoturbidimetry. One-to-three measurements for each patient were obtained; in case of multiple measurements, the geometric mean of 2–3 values was used for analysis. In individuals with multiple measurements, the concordance rate between the first value and the geometric mean was > 90% for all albuminuria categories. Patients were assigned to one of the following categories of albuminuria (mg/24 h): normoalbuminuria (A1, < 30), microalbuminuria (A2, 30–299), or macroalbuminuria (A3, > 300). Serum (and urine) creatinine was measured by the modified Jaffe method, traceable to IDMS, and eGFR was calculated by the CKD Epidemiology Collaboration equation. Patients were assigned to one of the following categories of eGFR (ml·min−1·1.73 m−2): G1 (> 90), G2 (60–89), G3 (30–59), and G4–5 (< 30). Based on albuminuria and eGFR values, patients were then classified into the following DKD phenotypes: no DKD, albuminuria alone (albuminuric DKD with preserved eGFR), reduced eGFR alone (nonalbuminuric DKD), or albuminuria and reduced eGFR (albuminuric DKD with reduced eGFR).

15In each centre, presence of diabetic retinopathy (DR) was evaluated by an expert ophthalmologist by dilated fundoscopy, with grade assigned based on the worst eye. Patients with mild or moderate non-proliferative DR were classified as having non-advanced DR, whereas those with severe non-proliferative DR, proliferative DR, or maculopathy were grouped into the advanced DR category.

16Prior major acute CVD events, including myocardial infarction, stroke, foot ulcer/gangrene/amputation, coronary, carotid, and lower limb revascularization, were adjudicated based on hospital discharge records by an ad hoc committee in each centre.

17As previously described, calculation of eGDR was performed according to the following formula: eGDR (mg/kg/min) = 21.158 − (0.09 × waist circumference) − (3.407 × hypertension) − (0.551 × HbA1c), where waist circumference is in cm, hypertension is 0 (no) or 1 (yes), and HbA1c is in %. As shown in Additional file 1: Figure S1, the correlation of eGDR calculated using this formula with glucose disposal rate (GDR) measured with euglycaemic-hyperinsulinemic clamp in 140 T2D patients was highly significant (r = 0.624; p < 0.0001); moreover, it was higher than that of Homeostasis Model Assessment – Insulin resistance (HOMA-IR) in the 85 patients with calculable values (r = 0.441; p < 0.0001) and similar to that reported in the validation study in T1D individuals. Participants were stratified in tertiles of eGDR calculated using either estimated waist circumference in the whole cohort, i.e. T3 (higher IR), ≤ 4.14; T2, 4.15–5.34; and T1 (lower IR), ≥ 5.35 mg/kg/min, or measured waist circumference in the 4618 individuals with available data, i.e. T3, ≤ 4.11; T2, 4.12–5.54; and T1, ≥ 5.55 mg/kg/min.

18Baseline data are expressed as mean ± SD or median (interquartile range) for continuous variables and number of cases (percentage) for categorical variables. Comparisons among eGDR tertiles were performed by one-way ANOVA or Kruskal–Wallis test, according to the parametric or non-parametric distribution of continuous variables, and by Pearson’s χ2 test for categorical variables.

19Binary logistic regression analyses were performed to explore the independent association of tertiles of eGDR (calculated using estimated waist circumference) with albuminuria and eGFR categories or DKD phenotypes at baseline (dependent variables); covariates were age, gender, smoking habits, diabetes duration, dyslipidaemia, non-advanced and advanced DR, prior CVD, cancer, and albuminuria or eGFR (as appropriate according to the dependent variable).

20Person-time in years was counted from the index date until the date of death or end of follow-up. Crude mortality rates were reported as events per 1000 person-years (PYs), with 95% Poisson confidence intervals (CIs). Death rates were also adjusted for age and eventually for gender by a Poisson regression model. Kaplan-Meier cumulative survival probabilities for all-cause mortality were estimated according to eGDR tertiles. Differences were analysed with the log-rank statistic. Relative risks according to eGDR tertiles were estimated by Cox proportional hazards regression, adjusted by age and gender (model 1), plus albuminuria and eGFR categories (model 2) or DKD phenotypes (model 3). Furthermore, model 4 and model 5 included the variables in model 2 and model 3, respectively, plus multiple confounders excluding variables entering the eGDR formula (waist circumference, HbA1c, and hypertension including BP-lowering treatment), i.e. CVD risk factors (smoking habits, diabetes duration, and dyslipidaemia) and complications/comorbidities (DR grade, prior CVD, and cancer). Results are expressed as hazard ratios (HRs) and their 95% CIs. The highest eGDR tertile (T1) was the reference category. Cox proportional hazards regression models were replicated after stratification by age (above and below the median value), gender, prior CVD and DKD phenotypes and appropriate tests were applied for assessing the interaction between each of these variables and the eGDR tertiles. Finally, regression models were rerun using tertiles of eGDR calculated from measured waist circumference.

21Tests were 2-sided, and a p value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL).

22Baseline characteristics of the study population stratified by eGDR tertiles are shown in Table 1.

23Compared with participants in the T1 group (reference), those in the T2 and T3 groups were more frequently females and former smokers, had longer diabetes duration, higher BMI, triglycerides, and non-HDL cholesterol, and lower HDL cholesterol, with no meaningful difference in total and LDL cholesterol. As expected, T2 and T3 participants had higher HbA1c, waist circumference, BP levels, and prevalence of hypertension, dyslipidaemia, and treatment with insulin, alone or combined with non-insulin agents, anti-hypertensive drugs, RAS blockers, and lipid-lowering agents.

24Levels of albuminuria and prevalence of micro and macroalbuminuria and of the albuminuric DKD phenotypes increased progressively from T1 to T3, whereas eGFR decreased and prevalence of nonalbuminuric DKD increased from T1 to T2, with no further change in T3. Prevalence of non-advanced and advanced DR and prior CVD, either as a whole or by vascular bed, increased from T1 to T3, whereas no difference was observed in cancer prevalence at baseline among eGDR tertiles.

25Binary logistic regression analyses exploring the relationship between eGDR tertiles and DKD showed an independent association with micro- and macroalbuminuria and the albuminuric DKD phenotypes (albuminuria alone or combined with reduced eGFR) as well as with eGFR categories and the nonalbuminuric DKD phenotype (Additional file 2: Table S1).

26The vital status on October 31, 2015, was retrieved for 15,656 participants (99.3% of the original cohort). A total of 3602 deaths occurred during the 116,100 PYs of follow-up (23.01%; 31.02 per 1000 PYs [95% CI 30.01–32.04]) over a mean observation of 7.42 ± 2.05 years. Death rates (Table 2), Kaplan-Meier estimates (Additional file 3: Figure S2) and unadjusted HRs (Fig. 1a) increased progressively across eGDR categories; however, the age-adjusted death rates for T2 and T1 were superimposable (Table 2), as those adjusted for age and gender (16.40 vs 16.74 per 1000 PYs, p = 0.620), with a significantly increased death rate vs T1 only for T3, i.e. for the subgroup with the lowest insulin sensitivity (22.35 per 1000 PYs when adjusting for age and gender, p < 0.0001).

27At Cox regression adjusted for age and gender (Fig. 1b, Additional file 4: Table S2, model 1) and for age, gender, and albuminuria and eGFR categories (Fig. 1c, Additional file 4: Table S2, model 2), the HRs vs T1 for all-cause mortality were increased for T3, but not for T2. Similar results were obtained by adjusting for DKD phenotypes in addition to age and gender (Additional file 4: Table S2, model 3). Further adjusting for several confounders, HRs for all-cause mortality remained higher for T3 vs T1 in either the model including albuminuria and eGFR categories (Fig. 1d, Additional file 5: Table S3, model 4) or that including DKD phenotypes (Additional file 5: Table S3, model 5).

28The results were similar when using tertiles of eGDR calculated from measured waist circumference in the 4618 individuals with available data (Additional file 6: Figure S3).

29Crude and age-adjusted death rates were increased for T3 vs T1 in individuals below and above median age and in both males and females, but only in participants without history of CVD (Table 3), whereas adjusted HRs were increased in both age groups (though more in younger than in older individuals), but only in males and participants with prior CVD, though interaction was significant only for age (Additional file 7: Table S4).

30After stratification by DKD phenotypes, age-adjusted death rates (Table 4) and adjusted HRs (Fig. 2) were higher for T3 vs T1 in individuals with no DKD and or nonalbuminuric DKD, but not in those with albuminuric DKD with preserved or reduced eGFR. The interaction between eGDR and DKD phenotypes was significant (p = 0.018).

31This analysis of the RIACE cohort of individuals with T2D showed a significant association between IR, as assessed by eGDR, and all-cause mortality. This relationship was independent of traditional CVD risk factors clustering with impaired insulin sensitivity as well as of cardiorenal complications and cancer, the risk of which has also been associated with IR. Regarding DKD, which was the main focus of our study, adjustment for albuminuria and eGFR or DKD phenotypes attenuated only slightly the association between eGDR and mortality, consistent with a previous report in T1D patients from the Swedish National Diabetes Register. However, two other studies in T1D individuals showed no significant association with all-cause mortality when serum creatinine and albuminuria and eGFR or DKD were included in the regression models. Likewise, in older adults without diabetes, the association of the insulin sensitivity index or fasting insulin concentration with all-cause mortality disappeared after adjustment for eGFR. Moreover, when adjusting for confounders including eGFR, glucose disposal rate measured by the euglycaemic hyperinsulinemic clamp technique was no longer associated with all-cause mortality in patients with chronic kidney disease (CKD) stages 3 and 4 and HOMA-IR was not an independent predictor of death in individuals with mild-to-moderate CKD from the Chronic Renal Insufficiency Cohort Study. Indeed, in our study, eGDR was independently associated with micro- and macroalbuminuria and the albuminuric DKD phenotypes, consistent with previous reports, as well as with eGFR categories or the nonalbuminuric DKD phenotype. However, eGDR was independently associated with all-cause death in individuals with no DKD or the nonalbuminuric DKD phenotype, but not in patients with albuminuria with preserved or reduced eGFR, suggesting that, in these individuals, the impact of IR on mortality is mediated by albuminuria.

32Taken together, these findings indicate that the impact of IR on mortality in T2D individuals is only partly mediated by the increased prevalence of CVD risk factors and complications/comorbidities, including DKD. This may imply either that IR exerts direct deleterious effects on survival or that the increased risk of death is explained by unmeasured confounders associated with IR or by the inability of “statistical” adjustment to fully account for the impact of measured confounders. Low-grade chronic inflammation, which is also associated with IR but was not accounted for in the regression models, may have played a role in favouring the increased mortality observed in the lowest eGDR tertile (T3). This interpretation is consistent with a previous study in diabetic patients showing that C-reactive protein (CRP) was an independent predictor of mortality in addition to IR. Moreover, the combination of IR, as assessed by HOMA-IR, and systemic inflammation, as assessed by CRP, was associated with all-cause and CVD mortality in community-dwelling older individuals from the InCHIANTI Study, whereas Lee et al. showed that CRP was an independent predictor of all-cause and cancer-related, but not CVD mortality, irrespective of HOMA-IR. Finally, CRP was included among the covariates that masked the association of the insulin sensitivity index or fasting insulin concentration with all-cause mortality in older adults without diabetes.

33To the best of our knowledge, this is the first study exploring the independent association of IR with mortality in a large sample of unselected patients with T2D. In fact, one study has previously assessed the ability of eGDR, as a measure of IR, to predict mortality in individuals with T2D and CAD who underwent coronary artery bypass grafting. This nationwide, population-based cohort study reported a significant independent association of the lowest vs the highest eGDR tertile with all-cause death [adjusted HR, 1.46 (95% CI, 1.12–1.90)] and a composite of major adverse CVD events and all-cause death (adjusted HR, 1.29 [95% CI 1.04–1.60]) over a 3.1-year follow-up in 3256 T2D patients. Consistently, another study in 350 Japanese patients with T2D reported that lower insulin sensitivity, measured as K index of the insulin tolerance test, was an independent predictor of all-cause mortality and CVD events.

34Conversely, more robust findings were reported in T1D, where eGDR was originally developed. An independent association was in fact shown with all-cause mortality and CAD over a 10-year follow-up in the Pittsburgh Epidemiology of Diabetes Complications Study and with all-cause mortality, CVD morbidity and mortality, and the combined end-point of CVD events and death over a 7.1-year follow-up in 17,050 individuals from the Swedish National Diabetes Register. Recently, a single-centre, 10-year observational study confirmed that eGDR was an independent predictor of major CVD events, CAD, and all-cause mortality in T1D patients.

35In our study, risk of death increased stepwise in T2 and T3 vs T1 (by 14% and 27%, respectively). However, after adjustment for age and gender, mortality risk was similar in T2 and T1, whereas it was 35% higher in T3 vs T1. Moreover, risk of death remained significantly higher in T3 vs T1 after further adjustment for albuminuria and eGFR or, alternatively, for DKD phenotypes (by approximately 20%) and even when other CVD risk factors, DR, CVD and cancer were included in the models (by 14%). Thus, in patients with T2D, the association between eGDR and all-cause death, thought significant, was less strong than that reported in patients with T1D. In fact, in T1D individuals, mortality risk was about 2.2-fold in those with the lowest compared to those with the highest eGDR values and was 40–50% lower for each SD increase in eGDR. These findings are consistent with the different weight of confounders such as traditional CVD risk factors and complications/comorbidities in the two clinical settings.

36To further explore the role of these confounders, we conducted subgroup analyses by gender, age, prior CVD, and DKD phenotypes. The finding that the association between eGDR and mortality was stronger in younger individuals and in those with no prior CVD (and DKD) is in keeping with the concept that the impact of IR per se on mortality risk is higher in individuals at lower risk, such as those with T1D. This interpretation is consistent with previous studies in nondiabetic individuals from the third National Health and Nutrition Examination Survey showing an independent association of IR, as assessed by HOMA-IR, with all-cause mortality only in those with normal BMI.

37Strengths of this study are the large sample size, the long observation period, the completeness of data collected at baseline and follow-up, the wide range of clinical parameters assessed, and the accurate determination of mortality due to the high quality of the Italian Health Card Database. There are also several limitations. First, as for other surrogate measures of IR, eGDR may not be as accurate as GDR assessed by the euglycaemic hyperinsulinemic clamp technique, which however is not applicable to large cohorts. Second, eGDR was validated against the euglycaemic hyperinsulinemic clamp technique in patients with T1D, though it was used also in those with T2D for assessing the relationship between IR and mortality. However, indices which require measurement of insulin (or C-peptide) levels, such as HOMA-IR, are not suitable for estimating insulin sensitivity in an unselected population of individuals with type 2 diabetes including a large proportion (~ 25) of insulin-treated patients such as the RIACE cohort. Moreover, we showed that eGDR correlated significantly (and better than HOMA-IR) with clamp-derived GDR data from T2D individuals. Third, eGDR was calculated using waist circumference estimated from BMI, but results did not change when repeating the analyses with eGDR calculated using measured waist circumference values, even in the smaller sample of 4618 individuals with available data. Fourth, the observational design makes causal interpretation impossible and does not allow to rule out the effect of unmeasured confounders, such as inflammatory markers. Fifth, the study findings may not be applicable to the general ambulatory population, as only part of the individuals with type 2 diabetes attend Diabetes Clinics in Italy. Finally, potential limitations concerning non-centralization of assessments of CVD risk factors and complications have been extensively addressed elsewhere.

38This study investigated the ability of IR, as assessed as eGDR, in predicting mortality in a large population of unselected T2D individuals. Participants in the lowest eGDR tertile (highest IR) had the worst CVD risk profile and the highest prevalence of DKD, DR, and prior CVD events, as compared with those in the highest eGDR tertile. After adjustment for all these confounders, including DKD, risk of death remained significantly associated with mortality, suggesting that IR is an independent predictor of death from any cause in T2D individuals. However, eGDR was independently associated with all-cause death in patients with no DKD and nonalbuminuric DKD, but not in those with the albuminuric phenotypes, suggesting that in these individuals the effect of eGDR was mediated by its strong independent association with albuminuria. Moreover, the impact of IR was stronger in males and in younger participants and was significant only in those without CVD. Our findings suggest including measures of IR to improve risk stratification for preventive and therapeutic purposes in individuals with T2D.